Livemint Recent deaths in Gambia, Uzbekistan and the US, allegedly caused by toxic drugs made in India, has the Centre reportedly planning to centralize drug regulation. How effective will this measure be? The Central Drugs Standard Control Organization (CDSCO) is the apex regulatory body. Each state has its own regulator. The state regulators look after licencing and audit manufacturing facilities while CDSCO is responsible for approving new drugs, imports of devices, clinical...

-The Tribune New Delhi: Amid the central government’s claim of 28 per cent higher yield of GM mustard in the Rajya Sabha, former government scientists and agriculture experts have accused the government of fiddling with GM DMH -11 data. The government is said to have claimed that there is 28 per cent higher yield of GM mustard than that of other varieties. Dr SE Pawar, who has worked at nuclear agriculture &...

-The Hindu This is the first time that a Central ministry has endorsed the safety and benefits of the seed in Parliament Field trials of the transgenic mustard variety, DMH-11, revealed them to be higher yielding and they didn’t deter the pollination habits of honey bees, Union science minister Jitendra Singh said in Rajya Sabha in a written response to a query. Dhara Mustard Hybrid-11 (DMH-11) had recently been approved by the Genetic...

-The Hindu “It would have been better if seed production trials take place in a controlled rather than in an open environment so as to assess various risks before conducting open field trials,” read a statement by the AIPSN. Following the go-ahead for production and field testing of hybrid seeds of genetically modified (GM) mustard, All-India Peoples Science Network (AIPSN) has demanded that the open field tests, if any, be conducted with...

-Hindustan Times On November 15, Boston-based health news website Stat News cited official documents that purported to detail a series of problems in how Bharat Biotech’s coronavirus vaccine, funded partly by the government, was approved. The Union government and vaccine maker Bharat Biotech on Thursday refuted a report that alleged rules and protocols were bent during the approval process for Covaxin, but the clarifications served to further add to the questions that...